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Summary 
The presence of cytotoxic T lymphocytes (CTL) to the gag antigens of human immunodeficiency 
virus (HIV) has been described in infected populations. We found that the majority of this immune 
response as measured in bulk CTL assays of unstimulated peripheral blood mononuclear cells 
(PBMC) is directed against the p24 component of the p55 gag precursor protein.  Using limiting 
dilution analysis of this effector cell population we confirm that the majority of activated gag- 
specific CTL  circulating in  the PBMC  of infected  hemophilic patients  are directed  at  p24 
determinants and are present at frequencies of 1/36,000 to 1/86,000 lymphocytes. By performing 
in vitro stimulation after limiting dilution, the precursor population of gag-specific CTL are 
characterized and quantitated.  HIV gag-specific CTL precursors are identified at frequencies of 
1/1700 to 1/17,000 lymphocytes and are made up of cells with both p17 and p24 specificities. 
No H1V gag-spedfic CTL precursor cells are identified in the PBMC of HIV-uninfected individuals. 
These studies demonstrate that CTL directed at both p17 and p24 determinants make up the 
cellular immune repertoire in HIVoinfected individuals but that only the p24-specific CTL are 
routinely found in an activated state in the circulation. 
T 
he CTL response has been shown to be an important 
factor in both the clearance of acute viral infections (1, 
2) and in the control of chronic viral infections (3). In recent 
years, the CTL response to HIV infection has been charac- 
terized by several groups of investigators (4-12). During the 
course of HIV infection a vigorous HIV-specific  CTL response 
is generated which declines only with terminal progression 
to AIDS (13). 
HIV-specific CTL responses directed against both struc- 
tural and nonstructural proteins of HIV have been described 
(4-12). Among the structural proteins, activated CTL to HIV 
gag proteins  are detectable in the PBMC of 25%  to 85% 
of seropositive patients in the absence of in vitro stimulation 
(4, 12, 14), and represents one of the most consistent HIV 
CTL responses. This vigorous cellular immune response is 
atypical of  other chronic viral infections.  To more closely  dissect 
this vigorous  cellular immune response, HIV-specific CTL 
clones have been generated from PBMC of infected individ- 
uals (7, 9,  15). In some of these studies, nonspecific T cell 
stimuli such as PHA or antibody to CD3 have been used 
to expand and clone the HIV-spedfic CTL (9,  15). While 
these stimuli are capable of activating HIV CTL, the already 
activated (DR +) CD8 + population which contains the HIV- 
specific CTL activity measured in the absence of in vitro stim- 
ulation (16, 17), is resistant to expansion via this mechanism 
(16). This would suggest that there exist two distinct HIV- 
specific CTL populations within the PBMC of infected indi- 
viduals: an activated population whose cytolytic  activity can 
be measured in bulk CTL assays in the absence of in vitro 
stimulation, and a memory population which can be acti- 
vated and expanded in response to non-specific stimulation. 
No studies have yet been performed however, to determine 
what portion of the total gag-specific response resides in ei- 
ther of these two CTL populations. 
The contribution to the total gag-specific CTL response 
of the structural components of gag is also unknown. Studies 
to date of bulk CTL lysis have used vaccinia vectors which 
express full length gag protein, and do not discriminate p17, 
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ping methods, CTL epitopes within both p17 and p24 have 
been identified. The frequency of activated and memory CTL 
to specific linear epitopes within the p24 antigen of HIV gag 
have been described in certain individuals  (14), however, these 
studies may underestimate the total CTL response of an in- 
dividual since  multiple CTL epitopes may be present in a 
single protein antigen (15, 18). In addition, the contribution 
of these and other epitopes to the total activated and memory 
gag-specific CTL repertoire have yet to be fully addressed (10, 
14, 18, 19). A better understanding of the total cellular im- 
mune response to the components of gag may have impor- 
tant implications for HIV vaccine development. 
In the studies described here, we have performed both bulk 
analysis and limiting dilution analysis on PBMC from HIV- 
infected hemophilic patients to quantitate the total activated 
and memory populations of HIV gag-specific CTL. In these 
studies, vaccinia vectors were specifically created to allow us 
to quantitate and characterize the CTL response to the major 
structural components (p17 and p24) as well as the precursor 
protein (p55) of the gag antigen. These studies allow a more 
comprehensive understanding of the HIV gag-specific  CTL 
repertoire. 
Materials and Methods 
Patient Population.  Patients were part of an ongoing study of 
immunoregulatory defects in hemophilia and were followed yearly 
at the New England Area Comprehensive  Hemophilia Center, Med- 
ical Center of Central Massachusetts-Memorial (Worcester, MA) 
(20). Patients gave informed consent before entering  study. Ap- 
proximately 90% are positive by Western blot for antibodies to 
HIV with the majority  having seroconverted before 1983. 
Effector Cells.  PBMC were isolated from freshly drawn hep- 
arinized venous blood by centrifugation on Ficoll-Paque  (Pharmacia 
Fine Chemicals, Piscataway, NJ) density gradients  (20). PBMC 
preparations contained 70% to 80% lymphocytes, 10% to 20% 
monocytes, and <20% polymorphonuclear  leukocytes  as determined 
by cell morphology. PBMC were used directly as effector cells in 
bulk CTL assays or subjected to limiting dilution  analysis as de- 
scribed below. 
Target Cell Lines.  Autologous B-lymphoblastoid cell lines (B- 
LCL)  ~ were created by incubation  of PBMC  with  supernatant 
from the EBV-producing  marmoset cell line B95.8 (NO. CRD1612; 
American Type Culture CoUection, Rockville, MD). Transformed 
cell lines were maintained in RPMI 1640 with 10% FCS. 
Vaccinia Virus Vectors.  Methods for the production,  propaga- 
tion and expression analysis of vaccinia  virus (W) vectors have  been 
previously described (12, 21). All VV incorporate sequences from 
the BH10 strain of HIV (22). Recombinant VV used in these studies 
include vAbT 141 which contains the entire HIV gag coding se- 
quence beginning at the translation initiation codon and extending 
approximately  200 bp beyond the gag translation termination codon. 
Recombinant vAbT 228 contains gag sequences from the initiation 
codon of gag through the PvulI site, 38 bp upstream of the end 
of p17 coding sequences. A synthetic linker was added to restore 
the terminal sequences of p17, along with a stop codon and a VV 
1 Abbreviations used in this paper: B-LCL, B-lymphoblastoid  call line; LDA, 
limiting dilution  analysis; MOI, multiplicity  of infection;  W, vaccim'a  virus. 
transcription termination sequence. Recombinant vAbT 286 con- 
tains the p24 coding sequence from nucleotide 508 through 1200 
removed from the intactgag gene. The 5  ~  and 3  ~  ends were modified 
using synthetic linkers to insert a BamHI site and a translational 
start codon at the beginning, and a translation termination codon 
and a KpnI site at the end of the coding sequence. Recombinant 
sequences were inserted in the tk (vAbT 141) or Hind-M  (vAbT 
228, 286) regions of VV and were under the control of the 7.5K 
(vAbT 141) or 40K (vAbT 228, 286) W  promoters. The predicted 
molecular sequences of the recombinant viruses were confirmed 
by restriction endonuclease  analysis and DNA hybridization of viral 
genomic DNA. Expression of appropriate recombinant proteins 
was confirmed  by in situ ELISA  and radioimmunoprecipitation  using 
polyclonal human serum from HIV-seropositive VV-seronegative 
donors. VV strain NYCBH was used as the control virus in all 
CTL studies. 
Radioimmunoprecipitation.  Target cells were infected with vac- 
cinia vectors at a multiplicity of infection (MOI) of 10 in the pres- 
ence of 100 #Ci of 3H-leucine (Dupont NEN, Boston, MA). Har- 
vesting and precipitation was performed as previously described 
(21) using HIV + VV-  human  serum. 
Bulk Cytotoxic T Lymphocyte Assays.  CTL assays using autolo- 
gous B-LCL infected with recombinant VV were performed as pre- 
viously described (12). All B-I.CL were infected with VV at MOI 
of 10 for 16 h before assay. VV-infected autologous B-LCL were 
labelled with S~Cr and used as targets in a standard 51Cr-release 
assay in which effector cells were freshly isolated PBMC from HIV- 
infected hemophilic patients. Effector-to-target (E/T) ratios of 50, 
25, and 12.5 to 1 were employed. Assays were performed in 96- 
well round-bottom microtiter plates containing 100 #1 of effector 
cell suspension and 100 #1 of target cell suspension. After 6 h of 
incubation at 37~  100/~1 of superuatant was removed from each 
well and counted in a gamma counter. Spontaneous release wells 
in which media (RPMI 1640, 10% FCS) was used in place of  effector 
cells were included in all assays. Assays were omitted from analysis 
if spontaneous release exceeded 30%. All tests were performed in 
triplicate wells. Maximal release was determined by counting the 
total cpm in a 50/~1 volume of target cell suspension. Percentage 
of specific cytolysis was calculated by the formula: 100  x  ([test 
cpm -  spontaneous cpm]/[maximal  cpm  -  spontaneous cpm]). 
Effector Cell Depletions.  Effector PBMC were depleted of cells 
expressing CD4 or CD8 surface antigens using mAbs OKT4 or 
OKT8 (Ortho Diagnostic Systems, Raritan, NJ) respectively, and 
rabbit complement (Cedarlane Laboratories, Ontario,  Canada) by 
previously published techniques (12, 21). Effector cells were then 
resuspended in the original (predepletion) volume of medium so 
nondepleted  cells would remain at predepletion  concentrations. Ade- 
quacy of depletions was assessed  by surface  phenotype analysis using 
direct  immunofluorescence with  PE-conjugated  Leu3a (Becton 
Dickinson  and  Co.,  Mountain  View, CA)  and ftuorescein iso- 
thiocyanate-conjugated  Leu2a (Becton Dickinson & Co.) using pre- 
viously published techniques (20). Samples  were analyzed  on a FAC- 
Scan (Becton Dickinson  & Co.). 
Limiting Dilution of  Activated Cytotoxic T Lymphocytes.  Relative 
frequencies of activated HIV gag-specific  CTL were determined 
using standard methods of limiting dilution analysis (LDA) (23). 
Freshly isolated PBMC were assayed at 1,563 to 100,000 lympho- 
cytes per well in 24 replicate wells for cytotoxicity on autologous 
B-LCL infected with NYCBH or recombinant W  expressing HIV 
gag proteins in a SlCr-release assay as described above. Fraction of 
nonresponding wells was taken as the number of wells in which 
SlCr-rehase did not exceed the mean plus three standard deviations 
of the spontaneous release of the 24 control wells, divided by 24. 
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distribution  analysis (23). 
Limiting Dilution Assays of Memory Cytotoxic T  Lymphocytes. 
Precursor frequencies of HIV gag-specific CTL were estimated by 
performing limiting  dilutions on freshly isolated PBMC followed 
by in vitro stimulation  to allow expansion of CTL. PBMC were 
diluted at 250 to 16,000 lymphocytes per well in 24 replicate wells 
of 96-well microtiter  plates. To each well was added 2.5  x  104 
gamma-irradiated PHA blasts from an HIV-seronegative donor and 
either 2 #g/ml of PHA (HA-16; Wellcome Diagnostics, Research 
Triangle Park, NC) or 2/zg/ml of mouse monoclonal anti-human 
CD3 (OKT3; Ortho Diagnostic  Systems). Cells were cultured at 
37~  5%  COz  in  RPMI  1640, 10%  FCS, 15%  human  IL-2 
(Pharmacia Fine Chemicals) for 5 d. Wells were then split and as- 
sayed for cytotoxicity on SlCr-labeled autologous B-LCL infected 
with vaccinia-HIV expression vectors. Fraction of nonresponding 
wells and precursor frequencies  were determined as described above. 
Statistical Analysis.  Simple  linear regression analysis was per- 
formed on LDA using least mean squared method. Frequency was 
determined by solving the equation  of the best fit line where the 
negative log of the fraction of nonresponding  wells equaled one 
(fraction of nonresponding  wells  =  0.37). 95% confidence limits 
were calculated based upon the true mean value of the dependent 
variable, lymphocytes per well. 
Results 
Human Immunodeficiency Virus Gag Antigens Are Expressed 
by Vaccinia Vectors.  Radioimmunoprecipitation was performed 
using HIV + VV-  human serum against cells infected with 
expression vectors vAbT 141, vAbT 228, and vAbT 286. Results 
are depicted in Fig. 1. Vector vAbT 141 produces a single band 
at p55 without evidence of processing to p24 and p17,  and 
vectors vAbT 228 and vAbT 286 produce single bands at p17 
and p24, respectively. All three vectors are strong expressers 
of HIV-1 gag  proteins. 
Human Immunodeficiency Virus Gag-specific Lysis Is Detect- 
able in Bulk Assays.  43 bulk CTL assays using PBMC from 
HIV seropositive hemophilic patients were performed at E/T 
ratios of 50, 25, and 12.5 to I against gag-expresfing  targets. 
16 assays included p17-expressing  targets and 7 assays included 
p24-expressing  targets  in  addition  to  the  p55-expressing 
targets.  Results of gag-spedfic  lysis from bulk CTL  assays 
at 50:1 E/T ratios are depicted in Fig. 2.  Cytolysis directed 
against p55 and p24 were readily detectable in PBMC from 
the majority of seropositve hemophilic patients tested (86% 
against either p55 or p24). In contrast, detection of cytolysis 
to p17 was infrequent, occurring in 3 of 16 (19%) seroposi- 
tive hemophilic patients. Cytolysis against p17 and p24 was 
always assayed in conjunction with p55 and in all cases where 
p17 or p24-specific lysis was observed, greater or equal cytol- 
ysis was observed against p55. Bulk cytolysis directed against 
HIV gag antigens was not detected in any of 8 seronegative 
subjects tested (data not shown). Vigorous cytolytic responses 
directed against p55 and p24 gag antigens are therefore de- 
tectable directly from PBMC of HIV-infected persons, while 
p17-specific  responses are much less  apparent. 
Bulk Gag-specific Cytolysis Is Mediated by Major Histocom- 
patibility Complex-restricted CD8 + Cytotoxic T  Lymphocytes. 
We have previously shown that bulk cytolysis directed against 
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Figure 1.  Expression  analysis of vaccinia vectors. Radioimmunoprecipi- 
rations were  performed on vector-infected  cells using HIV  +  , W-  human 
serum. Composite  of 2 separate  gels are shown. Lanes I and 4, NYCBH 
(VAC); lane 2, p55 expression  vector  vAbT 141; lanes 3 and 5, p17 expres- 
sion vector vAbT 228; lane 6, p24 expression vector vAbT 286. 
cells infected with vAbT 141 is blocked by antibodies to CD3, 
CD8,  and class I antigens  (12).  To confirm that bulk cyto- 
lytic responses against p55, p17 and p24-expressing targets 
are CD8-mediated, effector cells from a rare individual with 
bulk cytolysis against  all  three gag  antigens  were depleted 
of CD4 +  or  CD8 §  cells  through  complement-mediated, 
monoclonal  antibody-directed lysis.  As depicted in Fig.  3, 
CD4 depletion had little effect on gag-spedfic cytolysis, while 
CD8 depletion completely abrogated the gag-specific cyto- 
lytic  response.  In  addition,  HLA-mismatched  targets  ex- 
pressing p55, p17 or p24 were not efficiently recognized by 
the bulk effector cells (Fig. 3). As such, the effector cells medi- 
ating  bulk  p55,  p17  and  p24-specific cytolysis are MHC- 
restricted  CD8 + CTL. 
Activated Gag-specific Cytotoxic T Lymphocytes Can Be Quan- 
tiffed by Limiting Dilution Analysis.  Having shown that the 
circulating effector cells mediating gag-spedfic  cytolysis are 
CTL, we attempted to quantitate the frequency of these acti- 
vated ceils in the circulation of infected hemophilic patients. 
To  accomplish  this,  LDA was performed  on fresh PBMC 
preparations.  As shown in Fig. 4, no activated CTL to con- 
trol vaccinia-infected B-LCL targets  (i.e.,  vaccinia or EBV- 
specific  CTL) were detected at up to  105 effector ceils  per 
well, indicating  that  frequency determinations  based upon 80 
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Figure 2.  Bulk H[V gag-specific CTL responses.  Vaccinia-specific  cy- 
tolysis was subtracted from vaccinia/gag-specific cytolysis and is depicted 
for p55 (vAbT 141), p17 (vAbT 228) and p24 (vAbT 286)-expressing targets. 
Assays were performed at E/T of 50:1. Each point represents an individual 
assay on a specific HIV-seropositive hemophilic patient.  Total n of assays 
is as follows: 43 (p55),  16 (p17),  7  (p24).  The dashed line represents  2 
SDs above the mean vaccinia-specific cytolysis in these assays. 
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Figure 4.  Quantitation  of activated gag-spedfic  CTL. Limiting dilu- 
tion analysis was performed on freshly isolated PBMC from HIV-infected 
persons as described in the methods section. Targets were autologous B-I.CL 
infected with NYCBH (VAC), vAbT 141 (P55), vAbT 228 (P17), or vAbT 
286 (P24).  Effector cell frequencies were calculated as reciprocal of x vari- 
able where y  equals 0.37.  Frequencies for each target  are listed.  Those 
targets for which no frequency is listed were not calculable as all wells 
failed to exhibit significant cytolysis even at the highest effector cell con- 
centration. 
cytolysis of targets infected with recombinant VV expres- 
sion vectors reflect lysis by HIV gag-specific, and not vaccinia- 
specific CTL. Frequency determinations of p55-specific CTL 
for the three individuals depicted in Fig. 4 are 1/86,000, 
1/36,000,  and 1/84,000.  In the two individuals whose fre- 
quency of activated CTL against p24 and p17 were also de- 
termined, p24-specific CTL frequencies were similar to p55 
CTL frequencies, but p17 CTL frequencies were low to un- 
detectable (Fig. 4, lower 2 graphs). The frequency of p24- 
specific CTL actually appears greater than the frequency of 
p55 CTL in these two individuals but the 95%  confidence 
limits suggest no true difference  in these frequencies. All three 
individuals had CTL killing  directed against p55,  and the 
individuals depicted in the lower two graphs also had CTL 
killing directed at p24 but not p17 in bulk assays at an E/T 
ratio of 50:1. This indicates that virtually all the activated 
HIV gag-specific  CTL circulating  in these individuals  are 
directed towards p24 determinants and not p17 determinants. 
In addition, the lack of  cytolytic activity against p17-expressing 
targets at low effector cell input argues against a suppressor 
cell population as the cause for defident bulk p17 CTL activity. 
Precursor (Memory) Gag-specific Lysis Can Be Quantified after 
In Vitro Stimulation.  To determine if a population of  resting 
(memory) gag-specific  CTL precursors are also present at a 
given frequency in the PBMC of infected hemophilic patients, 
LDA followed by in vitro stimulation was performed. Stim- 
ulation with either PHA or anti-CD3 gave similar results 
in these assays and could be used interchangeably. The results 
of four separate precursor frequency determinations  on four 
individuals are presented in Fig. 5. The precursor frequency 
of p55-specific CTL in these four individuals ranged from 
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Figure 5.  Quantitation of memory gag-spedfic CTL. Limiting dilu- 
tion was performed on PBMC from HIV-infected  persons followed by in 
vitro stimulation with PHA or anti-CD3 as described  in the methods sec- 
tion. Targets  were autologous B-I.CL  infected  with NYCBH (VAC), vAbT 
141 (P55), vAbT 228 (P17), or vAbT 286 (P24). Precursor frequencies  were 
calculated as in Fig. 4. Results represent either PHA or anti-CD3 determi- 
nations based upon lowest background (VAC) precursor  frequencies.  Where 
no precursor frequency is listed, that frequency was not calculable as all 
wells failed to exhibit significant cytolysis  even at the highest effector  cell 
concentration. 
1/1,700  to 1/17,000.  This frequency is an order of magni- 
tude greater than the frequency of activated p55-specific CTL 
described in Fig. 4. The precursor frequency of p17 and p24- 
specific CTL was investigated in 2 of the 4 patients depicted 
in Fig.  5.  Both patients  had detectable bulk  CTL activity 
against p55 and p24, but not p17. In both individuals,  p17 
and p24-specific CTL are contributing to the memory p55- 
specific CTL population.  The p17-specific CTL are present 
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Figure 6.  Limiting dilution followed  by in vitro stimulation of PBMC 
from HIV uninfected donor. Targets and analysis performed as described 
in Fig. 5. 
at a precursor frequency of 1/1,400 to 1/4,100 PBMC while 
p24-specific CTL are present at 1/4,200 to 1/7,300 PBMC 
in these two individuals. This would indicate that while cir- 
culating activated piT-specific CTL are not routinely apparent 
in bulk CTL assays,  memory CTL with this specificity are 
a part  of the cellular anti-HIV repertoire. 
Gag-specific Lysis in Stimulated  Limiting Dilution  Analysis 
Is Mediated  by CD8 §  Cells.  While  we  have  shown  that 
the activated cells mediating gag-specific  cytolysis are MHC- 
restricted CD8 +  CTL,  the process of in vitro stimulation 
and culture in the presence of IL-2 could stimulate nonspecific 
cytolytic effector mechanisms  such as LAK cells (24).  We 
therefore sought to determine the phenotype of the cells being 
measured  in  the  stimulated  LDA  analyses.  PBMC  were 
depleted of CD4 + or CD8 + cells before LDA and in vitro 
Table  1.  Surface Phenotype of Memory Cytotoxic T  Lymphocyte 
Effector cells*  Not Depleted  CD4-depleted  CD8-depteted 
Precursor frequency of 
CTL with specificity* 
p55 
p17 
p24 
Surface  phenotype  s 
CD4 
CD8 
1/4,980 (1/3,910-6,060) 
1/19,600 (1/8,650-30,600) 
1/9,530  (1/5,780-13,300) 
1/6,550 (1/4620-8,470) 
1/28,600  (1/19,500-37,700) 
1/7,260  (1/4,410-10,100) 
1/26,700 (1/17,600-35,800) 
1/124,000  (1/85,900-161,000) 
1/23,000 (1/14,100-31,900) 
33%  <1%  74% 
48%  80%  4% 
* Effector cells were depleted of CD4 or CD8 cells using mAb-dependent, complement-mediated  lysis. Cells were then subjected to LDA followed 
by 5-d in vitro stimulation with anti-CD3 and expansion with IL-2. 
t Precursor frequencies of p55, p17, and p24-specific  effector cells in the depleted and nondepleted PBMC populations were determined as described 
in the methods section. Values in parentheses represent 95% confidence limits of the calculated frequencies. 
S Efficiency  of depletion was assessed by surface expression as determined by fluorescent mAb staining and FACS analysis. 
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mediating lysis of p55, p17 and p24-expressing targets were 
removed through CD8, but not CD4 depletion. The precursor 
cells which are expanded and assayed for in the stimulated 
LDA analyses are therefore CD8 + cells.  Because we use a 
nonspecific in vitro stimulation method which will stimu- 
late alloreactive CTL as well as virus-specific CTL, we were 
unable to demonstrate a MHC-restriction to the memory  gag- 
specific cytolysis through use of MHC-mismatched targets 
because of the high precursor frequencies of alloreactive CTL 
(data not shown). 
Gag-specific Cytotox~ T LyraFkocytes Are not Present in Human 
Immunodeficienff Virus Seronegative Individuals.  High precursor 
frequencies of gag-specific CTL should not be present in HIV- 
naive individuals. We therefore investigated the presence of 
gag-specific  CTL in HIV-seronegative individuals. We have 
previously reported that bulk CTL to HIV gag antigens are 
not detected in seronegative hemophilic patients (12). In ad- 
dition, we have been unable to detect activated gag-specific 
CTL  by  LDA  in  HIV-seronegative individuals  (data  not 
shown). As shown in Fig.  6, we were also unable to detect 
memory gag-specific  CTL after in vitro stimulation in HIV- 
seronegative individuals, supporting the conclusion that the 
cytolytic mechanisms being measured in these assays reflect 
virus-specific CTL activity. 
Discussion 
We have used bulk, unstimulated CTL assays and limiting 
dilution analysis to define the HIV gag-specific  CTL popula- 
tions present in the PBMC of infected hemophilic patients. 
The data support the presence of an activated gag-specific CTL 
population whose activity can be measured directly in the 
PBMC  of most infected individuals.  These activated gag- 
specific CTL are directed principally at p24 determinants and 
not p17 determinants, though we cannot rule out a concom- 
itant population of CTL with p15 specificity.  Direct deter- 
mination, through limiting dilution analysis, of the frequency 
of these activated gag-specific CTL in the PBMC of hemophilic 
patients indicates a frequency of 1/36,000 to 1/86,000. These 
determinations again indicate a paucity of activated piT-specific 
CTL in the circulation with virtually all p55-specific responses 
being attributable to p24 specificity. By using in vitro stimu- 
lation to expand all memory T cells (25), we have identified 
memory  gag-spedfic  CTL which exist at a frequency of 1/1,700 
to 1/17,000 in the PBMC of seropositive patients.  In con- 
trast to the activated CTL population, this memory popula- 
tion is composed of ceils directed against both p17 and p24 
determinants of the p55  major protein precursor. As such, 
the vigorous HIV gag-specific  CTL response which has been 
described in infected individuals represents the activity of only 
a small proportion of the total p24-specific  CTL repertoire, 
and does not reflect the p17-specific CTL population which 
is present but not in an activated state. 
All of the gag-spedfic effector  cells measured in these studies 
have been characterized as CD8 + cells. We and others have 
previously characterized the gag-specific  effector cell popula- 
tion responsible for the cytolysis seen in bulk assays as MHC 
class I-restricted, CD8 §  CD3 + CTL (11, 12, 14). No con- 
tribution of non-T cell or class II-restricted CTL have been 
identified for gag-spedfic  cytolysis (11, 12). In addition, un- 
like HIV envelope-specific  cytolysis, target ceils expressing 
gag antigens through W  expression vectors are not lysed 
through antibody-dependent cell-mediated cytotoxic or other 
non-MHC-restricted mechanisms (21). 
The fact that we were able to identify both p17 and p24- 
specific memory CTL populations within the PBMC of in- 
fected individuals is not surprising considering the fact that 
CTL epitopes within both p17 and p24 have been defined 
(10, 14, 18, 19). Our data suggest that CTL with both these 
specificities are part of the cellular immune response to HIV, 
but that the p24-specific response is more often activated in 
infected patients. 
Several hypotheses can be ruled out as explanations for the 
lack of activated piT-specific CTL in these patients. It is un- 
likely that a suppressor cell population exists which is effecting 
the p17-specific  CTL as this activity was not apparent  on 
LDA. The lack of p17-specific CTL also does not represent 
a problem with expression of p17 by the VV expression vector 
since piT-specific cytolysis can be measured after in vitro stim- 
ulation and plT-specitic CTL clones have been described which 
effciently recognize and lyse autologous target ceils infected 
with this W  expression vector (18). While loss of CD4 help 
in expanding virus-specific CTL clones has been described 
in HIV infection (26-28), it is unlikely that there is a specific 
defect in CD4 help which is hindering the expansion ofpl7- 
specific and not p24-specific  CTL. One could also hypothe- 
size that p17 does not contain CTL epitopes which are re- 
stricted  by common HLA  haplotypes,  but  the  fact  that 
piT-specific CTL are found after in vitro stimulation (18, 19) 
and that T cell epitopes have been identified within p17 by 
computer modeling (29)  argues against this point. 
It may be more appropriate to ask why the p24-specific 
CTL are so often found in an activated state in these patients, 
since this level of activated CTL has not been described for 
other chronic viral infections (3).  However, more informa- 
tion regarding the number of potential CTL epitopes con- 
tained within the p24 molecule, and the role of infection of 
antigen presenting cells, such as monocytes/macrophages and 
dendritic ceils, is required to adequately address the mecha- 
nisms underlying this high degree of specific CTL activation. 
A recent report described precursor frequencies of 1/3,500 
and 1/8,000 PMBC for p24 epitope-specific memory CTL 
in two infected individuals (14). These frequencies are similar 
to those reported here. In their report however, Gotch et al. 
(14) find a much higher frequency of activated p24 epitope- 
specific CTL (1/100-1/1,000  PBMC) than we report. This 
discrepancy probably relates to the different methods used 
to calculate the frequency of the activated CTL population. 
We use LDA analysis as performed by other investigators (13, 
30) to calculate the frequency of activated CTL while Gotch 
et al.  (14) derive their frequencies by comparing bulk p24- 
specific cytolysis with the cytolysis observed at varying E/T 
ratios for a CTL clone. In our analysis it is assumed that one 
CTL in an assay well is sufficient to mediate cytolysis greater 
than 3 SDs above the mean cytolysis,  where in the analysis 
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CTL cells are capable of active cytolysis. Preliminary results 
from LDA of a p24-specific done (kindly provided by R. 
Paul Johnson, Massachusetts General Hospital, Boston, MA) 
performed in our laboratory indicate that greater than  500 
cloned CTL are required to lyse the approximately 150 target 
cells needed to observe ;>3 SDs of killing  above the mean 
(data not shown). This would indicate that not all cells within 
a CTL done are capable at any given time of efficiently lysing 
appropriate target cells, and could be one explanation for the 
discrepancy between our data and that of Gotch et al.  (14). 
Precursor frequencies of HIV envelope-specific CTL have 
been described (13). LDA of HIV envelope-specific CTL sug- 
gests a high precursor frequency even in seronegative sub- 
jects (13). Similar LDA studies in SIV-infected macaques found 
the effector cell population of envelope-specific killer cells to 
be composed of both MHC-restricted and nonrestricted cells 
(30) raising the possibility that the high HIV envelope CTL 
precursor frequency described on HIV-seronegative subjects 
may be mediated by nonspecific effector cell mechanisms and 
not CTL. Since a nonspecific effector cell mechanism forgag- 
specific cytolysis has not been described and gag-specific CTL 
precursors are not found in seronegative subjects, the con- 
cerns raised by the envelope CTL work do not apply to the 
gag-specific CTL precursor frequency determinations described 
here. 
The studies described above have implications for the de- 
velopment of an HIV vaccine.  HIV gag antigens are clearly 
recognized by the human immune system and a broad CTL 
response is generated  to epitopes within both the p17 and 
p24 antigens. As such, these antigens may play an important 
role in protective immunity against this virus infection and 
should be not overlooked in the development of effective vac- 
cine strategies. 
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